396 related articles for article (PubMed ID: 23803853)
1. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.
Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853
[TBL] [Abstract][Full Text] [Related]
2. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.
Villalonga P; Fernández de Mattos S; Ridley AJ
J Biol Chem; 2009 Dec; 284(51):35287-96. PubMed ID: 19850923
[TBL] [Abstract][Full Text] [Related]
3. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
Ravitz MJ; Chen L; Lynch M; Schmidt EV
Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.
Martin D; Nguyen Q; Molinolo A; Gutkind JS
Oncogene; 2014 May; 33(18):2405-12. PubMed ID: 23708663
[TBL] [Abstract][Full Text] [Related]
5. The translational landscape of mTOR signalling steers cancer initiation and metastasis.
Hsieh AC; Liu Y; Edlind MP; Ingolia NT; Janes MR; Sher A; Shi EY; Stumpf CR; Christensen C; Bonham MJ; Wang S; Ren P; Martin M; Jessen K; Feldman ME; Weissman JS; Shokat KM; Rommel C; Ruggero D
Nature; 2012 Feb; 485(7396):55-61. PubMed ID: 22367541
[TBL] [Abstract][Full Text] [Related]
6. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth.
Lynch M; Fitzgerald C; Johnston KA; Wang S; Schmidt EV
J Biol Chem; 2004 Jan; 279(5):3327-39. PubMed ID: 14607835
[TBL] [Abstract][Full Text] [Related]
7. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
9. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
10. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
[TBL] [Abstract][Full Text] [Related]
11. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
12. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.
Satheesha S; Cookson VJ; Coleman LJ; Ingram N; Madhok B; Hanby AM; Suleman CA; Sabine VS; Macaskill EJ; Bartlett JM; Dixon JM; McElwaine JN; Hughes TA
Mol Cancer; 2011 Feb; 10():19. PubMed ID: 21320304
[TBL] [Abstract][Full Text] [Related]
13. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.
Mallya S; Fitch BA; Lee JS; So L; Janes MR; Fruman DA
PLoS One; 2014; 9(2):e88865. PubMed ID: 24586420
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
Rutkovsky AC; Yeh ES; Guest ST; Findlay VJ; Muise-Helmericks RC; Armeson K; Ethier SP
BMC Cancer; 2019 May; 19(1):491. PubMed ID: 31122207
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of mTOR signaling is involved in thymic lymphoma development in Atm-/- mice.
Kuang X; Shen J; Wong PK; Yan M
Biochem Biophys Res Commun; 2009 Jun; 383(3):368-72. PubMed ID: 19364503
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
17. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.
Hussain S; Bedekovics T; Liu Q; Hu W; Jeon H; Johnson SH; Vasmatzis G; May DG; Roux KJ; Galardy PJ
Blood; 2018 Dec; 132(24):2564-2574. PubMed ID: 30257881
[TBL] [Abstract][Full Text] [Related]
18. Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E.
ur Rasool R; Rah B; Amin H; Nayak D; Chakraborty S; Rawoof A; Mintoo MJ; Yousuf K; Mukherjee D; Kumar LD; Mondhe DM; Goswami A
Sci Rep; 2016 Jan; 6():18800. PubMed ID: 26728896
[TBL] [Abstract][Full Text] [Related]
19. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.
Fingar DC; Salama S; Tsou C; Harlow E; Blenis J
Genes Dev; 2002 Jun; 16(12):1472-87. PubMed ID: 12080086
[TBL] [Abstract][Full Text] [Related]
20. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.
Metcalfe C; Ibrahim AE; Graeb M; de la Roche M; Schwarz-Romond T; Fiedler M; Winton DJ; Corfield A; Bienz M
Cancer Res; 2010 Aug; 70(16):6629-38. PubMed ID: 20663899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
